EU approves Prilocaine Lidocaine Plethora to treat Premature Ejaculation-Plethora
Plethora Solutions Holdings plc (a Subsidiary of Shionogi) announced that the European Commission has granted marketing authorisation for the Company�s treatment for primary Premature Ejaculation in adult men under the name �Prilocaine Lidocaine Plethora�. This product is also referred to by the Company under its development code PSD 502.
PSD 502 was developed by the Company for the treatment of primary Premature Ejaculation and demonstrated a highly statistically and clinically significant improvement in the primary measures of intravaginal ejaculation latency time (IELT), control and satisfaction in two pivotal, double-blind, placebo controlled phase III studies. In these studies, the product was shown in over 23,000 exposures to be well accepted by patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.